Beneficial Effects of Testosterone Therapy on Functional Capacity, Cardiovascular Parameters, and Quality of Life in Patients with Congestive Heart Failure

Table 4

Changes in cardiovascular parameters, quality of life, and depression score.

Item	Testosterone group		Placebo group		𝑃 value
	Baseline	Endpoint	Baseline	Endpoint
Quality of life	128.96±4.91	130.95±2.84	128.00±4.56	127.50±3.44	0.002
Beck score	4.60±4.41	5.00±6.28	4.63±3.14	5.55±5.50	0.152
End diastolic diameter	5.94±1.06	5.86±0.98	5.90±0.82	5.66±0.79	0.440
End systolic diameter	4.92±1.02	4.66±1.06	6.87±1.27	4.49±0.89	0.557
End diastolic volume	141.44±54.06	137.28±48.56	149.16±46.51	130.26±50.72	0.627
End systolic volume	88.72±35.63	87.76±40.80	94.56±43.75	87.04±36.40	0.949
Ejection fraction	34.52±7.39	37.12±8.23	30.76±7.99	35.00±7.91	0.368
Tei index*	0.54±0.02	0.47±0.01	0.55±0.02	0.59±0.02	0.025

∗The pulsed Doppler Tei index is a parameter to evaluate combined systolic and diastolic cardiac performance that is measured by dividing Isovolumic contraction time plus isovolumic relaxation time by ejection time.
Data are presented as mean ± SD.